ライフサイエンスコーパス: EDSS

1 EDSS Expanded Disability Status Scale and MSFC MS functi

2 EDSS remained low over time with a median of 1.5 in both

3 EDSS score correlated with TSC increases inside motor ne

4 EDSS scores increased by a median 1 point (interquartile

5 d to exist despite a difference of up to 1.0 EDSS point (two 0.5 steps), 13 SNRS points, 9 FIM points

6 nes (EDSS 4.0, 23.8 vs 15.5 years, p<0.0001; EDSS 6.0, 30.8 vs 20.4 years, p<0.0001; EDSS 8.0, 44.7 v

7 001; EDSS 6.0, 30.8 vs 20.4 years, p<0.0001; EDSS 8.0, 44.7 vs 39 years, p=0.02), but did so between

8 cale (EDSS) 4.0:8.1 vs. 17.1 years, p<0.001; EDSS 6.0: 9.6 vs. 22.1 years, p<0.001; EDSS 8.0: 20.7 vs

9 .001; EDSS 6.0: 9.6 vs. 22.1 years, p<0.001; EDSS 8.0: 20.7 vs. 39.7 years, p<0.001), but there were

10 lesions (p=0.007), new T2 lesions (p=0.015), EDSS progression (p=0.034), and relapses in patients wit

11 cantly higher EDSS increase during PML (0.09 EDSS points per month; p = 0.04) as compared to those wh

12 bility (an EDSS score increase of at least 1 EDSS point sustained for a minimum of 12 weeks), both an

13 worsening (worst quartile of change, >/=4.5 EDSS points) during the 15-year interval.

14 posure as the most protective factor against EDSS-worsening events and relapses as the most important

15 to sustained accumulation of disability (an EDSS score increase of at least 1 EDSS point sustained f

16 gnancy had no effect on the time to reach an EDSS score 6.

17 erval [CI] = 7.2-14%) of patients reached an EDSS >/= 6, and 18.1% (95% CI = 13.5-22.5%) evolved from

18 cant difference in the hazard of reaching an EDSS score of 6 when either the contemporary control coh

19 low-up would be required in patients with an EDSS of 6.0 or less before drawing conclusions on this s

20 1.04-8.98; P = .04) were associated with an EDSS value of at least 2.5 at 60 months.

21 ce interval [CI] = 1.21-3.10, p = 0.006) and EDSS worsening (97.5th percentile: OR = 2.41, 95% CI = 1

22 The correlation between brain atrophy and EDSS score was better in patients with secondary progres

23 confounders (sex, age, disease duration, and EDSS score), exposure to interferon beta was not associa

24 PASAT, z-score, MSIS-29 (psychological) and EDSS and MRI cerebral atrophy and MTR.

25 with EDSS >/= 4 or >/= 6, </= 5 relapses and EDSS <4 or <6, and time to conversion to secondary-progr

26 dity of these scales as impairment (SNRS and EDSS) and disability (EDSS, FIM, AI and the disability d

27 ber of previous relapses within 2 years, and EDSS.

28 the most important risk factor for attaining EDSS worsening.

29 secutive months for patients with a baseline EDSS >/=2), and analysed efficacy outcomes for subgroups

30 For the 199 patients with a baseline EDSS score greater than or equal to 2, SRD was more like

31 ment, region, disease duration, and baseline EDSS score.

32 An elevated baseline EDSS score (odds ratio [OR] per point, 1.92; 95% CI, 1.5

33 I, 2.31-19.7; P < .001), and higher baseline EDSS score (HR per point, 1.21; 95% CI, 1.06-1.39; P = .

34 MS therapy, in patients with lower baseline EDSS scores, and in patients with lower prenatalizumab r

35 with disease duration >10 years was better (EDSS 1.5) compared with a population-based multiple scle

36 ions of all five scales were either bimodal (EDSS and AI) or severely skewed (SNRS, FIM and CAMBS).

37 e number of lesions at presentation and both EDSS (r = 0.45, P < 0.001) and the type of disease at fo

38 in neurological disability, as determined by EDSS score (p<0.0001), neurological rating scale score (

39 SIENA, which was independently predicted by EDSS (P = 0.004).

40 --including 26 (39%) with a 'benign' course (EDSS < or = 3)--whilst 28 (42%) had developed secondary

41 correlation was found between WBNAA deficit, EDSS score, and age.

42 s impairment (SNRS and EDSS) and disability (EDSS, FIM, AI and the disability domain of the CAMBS) me

43 relapsing-remitting MS and mild disability (EDSS - Expanded Disability Status Scale 1-3.5) and 16 co

44 mbulation (AI > or =7) or severe disability (EDSS >6.5) had significantly higher CSF GFAP levels than

45 ly Living (ADL) Index of general disability, EDSS, a 0-4 ataxia scale, Mini-Mental State (MMS) examin

46 om 11 (20%) had relapsing/remitting disease (EDSS > 3), 13 (24%) secondary progressive and 21 (39%) b

47 lerosis cohort matched for disease duration (EDSS 3.5; P < 0.001).

48 f these data indicated that trials employing EDSS change of 1.0 as the primary outcome measure would

49 ificant spinal cord parameter for explaining EDSS score.

50 a significantly higher incidence of a first EDSS-worsening event in patients with multifocal or isol

51 owever, trials including patients with fixed EDSS of >/=6.0 will be underpowered even with large numb

52 A ratio of less than 100% for EDSS implied slower than expected progression on treatme

53 145 patients in the dronabinol group had EDSS score progression (0.24 first progression events pe

54 o underwent proST had a significantly higher EDSS increase during PML (0.09 EDSS points per month; p

55 >5 cm was associated with a slightly higher EDSS at last follow-up, long-term prognosis in patients

56 e were significant correlations between: (i) EDSS and m-Ins, Cho, Cr and radial diffusivity of the la

57 Change in EDSS from baseline to 24 months was a strong predictor o

58 een change in T2 lesion volume and change in EDSS grade (P = .42) or AI (P = .37) was found.

59 etter clinical outcomes, and early change in EDSS score may have prognostic value, over many years, i

60 of change in T2 lesion volume with change in EDSS was most evident in years 0-5 (r(s) = 0.69, P < 0.0

61 y Status Scale (EDSS) progression, change in EDSS, proportions of patients with EDSS >/= 4 or >/= 6,

62 me: -0.11, 95% CI = -0.25 to 0.04; change in EDSS: -0.01, 95% CI = -0.09 to 0.08; relapse rate: HR =

63 icant improvement in disability (decrease in EDSS score of >/=1.0) in 41 patients (50%; 95% CI, 39% t

64 th groups had a significant deterioration in EDSS but not Barthel ADL Index scores at 1 year, but the

65 e free from progression (no deterioration in EDSS score), and 16 were free of relapses.

66 moderate correlation between the increase in EDSS and temporal and superior RNFL thinning.

67 Associations were seen between increase in EDSS score and decrease in cord area (r=0.31, P<0.05) an

68 progression using 600 patients with initial EDSS of 4.0 per trial arm, or 400 patients with initial

69 per trial arm, or 400 patients with initial EDSS of 5.0 per arm.

70 median active follow-up times (first to last EDSS measurement) were as follows: for the interferon be

71 sure was independently associated with lower EDSS at 10 years (coeff = -0.86, p = 1.3 x 10(-9) ).

72 ere also independently associated with lower EDSS scores over the 10-year observation period (coeff =

73 Mean EDSS scores remained unchanged up to 5 years.

74 8% women, mean age 48.5 years [SD 8.4], mean EDSS 4.67 [SD 1.03], 87% free of gadolinium-enhancing le

75 Median EDSS score changes over a 10-year period were determined

76 e to second attack was 4.8 years, and median EDSS at follow-up was 3.0.

77 was highly predictive of increases in median EDSS over 10 years (coeff = 1.14, p = 1.9 x 10(-22) ).

78 3 male; 10 female; mean age 52 years; median EDSS 6.0; mean disease duration 11 years), and 27 patien

79 8 male; 19 female; mean age 50 years; median EDSS 6; mean disease duration 22 years).

80 =0.0001) and to reach disability milestones (EDSS 4.0, 23.8 vs 15.5 years, p<0.0001; EDSS 6.0, 30.8 v

81 Predictors of EDSS change were then assessed using median quantile reg

82 RSS inclusion criteria and had at least one EDSS score after baseline.

83 of disease onset, gender disease duration or EDSS, but there was a strong correlation with the number

84 nd change in brain volume, relapse rates, or EDSS scores.

85 Meier estimate of progression (>/= 1.0 point EDSS) at 3 years was 27%.

86 any of 9 patients with a pretransplantation EDSS of 6.0 or less.

87 re were 2 patients with a pretransplantation EDSS of 7.0 and 8.0 who died from complications of progr

88 nt) on the Expanded Disability Status Scale (EDSS) (range, 0-10, with higher scores indicating higher

89 s, time to Expanded Disability Status Scale (EDSS) 4.0, 6.0 and 8.0 and onset of secondary progressio

90 n in ROMS (Expanded Disability Status Scale (EDSS) 4.0:8.1 vs. 17.1 years, p<0.001; EDSS 6.0: 9.6 vs.

91 using the expanded disability status scale (EDSS) and motor components of the MS functional composit

92 using the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC)

93 clinical [Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite Measur

94 red on the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite.

95 iated with Expanded Disability Status Scale (EDSS) assessments (beta = 1.105, p < 0.001) and presence

96 ing serial Expanded Disability Status Scale (EDSS) assessments, from all 87 patients treated with ale

97 ned by the expanded disability status scale (EDSS) did not increase in disability by 1.0 or more step

98 e absolute expanded disability status scale (EDSS) grade (P = .32) or the absolute ambulation index (

99 s, time to Expanded Disability Status Scale (EDSS) progression, change in EDSS, proportions of patien

100 r younger, Expanded Disability Status Scale (EDSS) score 6.5 or lower, and no more than 10 years sinc

101 WBNAA and Expanded Disability Status Scale (EDSS) score and Mann-Whitney analyses to test for differ

102 ed both in Expanded Disability Status Scale (EDSS) score and utility.

103 ine of the Expanded Disability Status Scale (EDSS) score at 60 months after the diagnosis, overall su

104 trophy and Expanded Disability Status Scale (EDSS) score in patients with secondary progressive MS (r

105 sustained Expanded Disability Status Scale (EDSS) score increase)) continued original treatment (thr

106 rs, had an Expanded Disability Status Scale (EDSS) score of 0-5.0, and had either one or more relapse

107 nge in the Expanded Disability Status Scale (EDSS) score of 1.0 or greater (score range, 0-10).

108 ys, and an Expanded Disability Status Scale (EDSS) score of 5.5 points or less.

109 o reach an Expanded Disability Status Scale (EDSS) score of 6 (mean 22.9 years) and patients having c

110 d the mean expanded disability status scale (EDSS) score of the alemtuzumab cohort improved compared

111 Mean Expanded Disability Status Scale (EDSS) score was 3.5.

112 change in expanded disability status scale (EDSS) score, and no new MRI lesions (no T1 gadolinium-en

113 cording to expanded disability status scale (EDSS) score, centre, and disease type.

114 , although expanded disability status scale (EDSS) scores were not significantly different (5.2 [1.0-

115 Expanded Disability Status Scale (EDSS) scores were unchanged, except for improved bowel a

116 Expanded Disability Status Scale (EDSS) scores, disease duration, treatments, prior optic

117 n baseline expanded disability status scale (EDSS) was 7.0 (range, 5.0-8.0).

118 red by the Expanded Disability Status Scale (EDSS) was stable or improved compared to baseline in 41%

119 ing severe Expanded Disability Status Scale (EDSS) worsening (worst quartile of change, >/=4.5 EDSS p

120 aseline in Expanded Disability Status Scale (EDSS), 25' Timed-Walk Test, or Nine-Hole Peg Test to ass

121 sed on the Expanded Disability Status Scale (EDSS), 9-hole peg test (HPT) and timed 25-foot walk test

122 he Kurtzke expanded disability status scale (EDSS), and five patients (24%) relapsed but achieved rem

123 abilities [Expanded Disability Status Scale (EDSS), score 3.5-8], with a median disease duration of 1

124 rosis, the Expanded Disability Status Scale (EDSS), the Scripps Neurological Rating Scale (SNRS), the

125 d with the Expanded Disability Status Scale (EDSS), the timed 25-foot walk test (TWT), and the nine-h

126 lated with Extended Disability Status Scale (EDSS), time since CIS diagnosis, time since MS diagnosis

127 of a first Expanded Disability Status Scale (EDSS)-worsening event (HR, 95% CI = 0.59, 0.42-0.83; 0.7

128 Kurtzke's expanded disability status scale (EDSS).

129 he Kurtzke Expanded Disability Status Scale (EDSS).

130 using the Expanded Disability Status Scale (EDSS).

131 ned by the Expanded Disability Status Scale (EDSS).

132 red by the Expanded Disability Status Scale (EDSS).

133 linked to Expanded Disability Status Scale (EDSS).

134 al scores (Expanded Disability Status Scale [EDSS] and MS multiple sclerosis Functional Composite [ M

135 d with the Expanded Disability Status Scale [EDSS] score; P = .046, corrected) and lesion load at T2-

136 data (the expanded disability status scale [EDSS] time series) obtained from a retrospective longitu

137 ion to MS, Expanded Disability Status Scale [EDSS]) and magnetic resonance imaging (MRI) outcomes.

138 isability (Expanded Disability Status Scale [EDSS]).

139 y means of Expanded Disability Status Scale [EDSS]).

140 the Expanded Disability Status Scale score (EDSS) and the 9-hole PEG test (9HPT).

141 patients [Extended Disability Status Score (EDSS) 0-7.5] with relapsing-remitting multiple sclerosis

142 areas and Expanded Disability Status Score (EDSS) were determined.

143 h high pretransplantation disability scores (EDSS > 6.0), progressive neurologic disability as define

144 age, sex, expanded disability system scores (EDSS) and disease duration.

145 persistent disease activity predicted severe EDSS worsening: gadolinium-enhancing lesions (odds ratio

146 Both models showed slower EDSS progression than predicted for untreated controls (

147 s to test for differences between subgroups' EDSS scores versus previously published WBNAA values for

148 erved outcome rates for reaching a sustained EDSS score of 6 were 10.8%, 5.3%, and 23.1% in the 3 coh

149 ced a significant delay in time to sustained EDSS progression (p = 0.02).

150 The SNRS and the EDSS were reliable and valid measures of impairment and

151 S were sensitive to clinical change, but the EDSS and the SNRS were unresponsive.

152 Except for the EDSS model, all associations were stronger when the with

153 Scores from the EDSS improved significantly from a pretransplant median

154 sing global disability (as assessed from the EDSS score).

155 in the datasets was reduced by grouping the EDSS time series using an unsupervised clustering analys

156 efined by at least a 1-point increase in the EDSS has occurred and was manifested as gradual neurolog

157 servation predicted subsequent change in the EDSS, suggesting that the MSFC is more sensitive to chan

158 = .03) were associated with worsening of the EDSS score at 60 months.

159 isability (SRD; a >/=1 point decrease on the EDSS sustained for 6 consecutive months for patients wit

160 he MSFC is more sensitive to change than the EDSS.

161 M-Ins was independently associated with the EDSS, while Cr, tNAA and connectivity of the posterior t

162 ng physical disability, as measured with the EDSS.

163 n and spinal GM independently contributed to EDSS.

164 s who did the OCT at baseline were masked to EDSS results and the researchers assessing disability wi

165 m-enhancing lesion number, T2 lesion volume, EDSS score, number of previous relapses, and highly acti

166 Primary outcomes were EDSS score progression (masked assessor, time to progres

167 ients with a three-year follow-up, for which EDSS data and brain volume time series were available.

168 , p<0.01) were independently associated with EDSS (R(2)=0.77); spinal cord GM RD was also independent

169 S versus HCs, and showed an association with EDSS and disease duration.

170 d whole cord areas inversely correlated with EDSS (rho: -0.60, -0.32, -0.42, respectively; all p </=

171 (P=.003, Wilcoxon test) and correlated with EDSS score (Spearman rho=0.19, P=.04) and brain atrophy

172 UCCA was inversely correlated with EDSS score, TWT, and nine-hole peg test findings (rho </

173 Cortical lesion volume correlated with EDSS scores more robustly than did WM lesion volume (rho

174 0.44, P < .01) were strongly correlated with EDSS.

175 nd the researchers assessing disability with EDSS were masked to OCT results.

176 significantly increased in participants with EDSS scores of 5.0 or more vs those with scores less tha

177 change in EDSS, proportions of patients with EDSS >/= 4 or >/= 6, </= 5 relapses and EDSS <4 or <6, a

178 ated with lower proportions of patients with EDSS progression and conversion to SPMS, and longer time

179 nd 21 (39%) benign (relapsing/remitting with EDSS < or = 3) disease.

180 on) on QS maps correlated significantly with EDSS (R = 0.46, P = .02).

181 Both effects correlated strongly with EDSS.

182 me-points correlated moderately with 20-year EDSS (r(s) values 0.48 to 0.67; P < 0.001) and MSFC z-sc